FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
Original source ↗  |  February 17, 2026 at 13:00 UTC  |  Finnhub - JNJ

No analysis available.

Trade Ideas
Ticker Direction Speaker Thesis Time
JNJ
NONE Finnhub News — —